WBP 216

Drug Profile

WBP 216

Alternative Names: Long-acting anti-IL6 antibody - MedImmune; MEDI-5117; WBP216

Latest Information Update: 23 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MedImmune
  • Developer MedImmune; WuXi AppTec
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders
  • No development reported Inflammation
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 18 Jan 2017 China Food and Drug Administration approves IND application for WBP 216 in Rheumatoid arthritis
  • 18 Jan 2017 WuXi-MedImmune plans a phase I trial for Rheumatoid arthritis in China
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in China (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top